2-(5-chlorothiophen-2-yl)-1H-1,3-benzodiazole-6-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(5-chlorothiophen-2-yl)-1H-1,3-benzodiazole-6-carboxylic acid
• 英文别名: 2-(5-chlorothiophen-2-yl)-3H-benzimidazole-5-carboxylic acid
• 化学式: C₁₂H₇ClN₂O₂S
• mdl: MFCD17932997
• 分子量: 278.719
• InChiKey: ZUJDPHAAMYVEKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-氨基苯基)吗啡啉-3-酮 、 2-(5-chlorothiophen-2-yl)-1H-1,3-benzodiazole-6-carboxylic acid 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(5-Chloro-thiophen-2-yl)-1H-benzoimidazole-5-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide
  参考文献：
  名称：

  Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa

  摘要：

  Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.097
• 作为产物：
  描述：

  3,4-二氨基苯甲酸乙酯 在 sodium hydroxide 、 sodium hydrogensulfite 作用下， 以 N-甲基吡咯烷酮 、 甲醇 为溶剂， 生成 2-(5-chlorothiophen-2-yl)-1H-1,3-benzodiazole-6-carboxylic acid
  参考文献：
  名称：

  Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa

  摘要：

  Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.097

文献信息

• Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines
  作者：Rafał Moszczyński-Pętkowski、Jakub Majer、Małgorzata Borkowska、Łukasz Bojarski、Sylwia Janowska、Mikołaj Matłoka、Filip Stefaniak、Damian Smuga、Katarzyna Bazydło、Krzysztof Dubiel、Maciej Wieczorek

  DOI：10.1016/j.ejmech.2018.05.043

  日期：2018.7

  compounds containing [1,2,4]triazolo [1,5-a]pyridine (I), pyrazolo [1,5-a]pyridine (II), 1H-1,3-benzodiazole (III) and imidazo [1,2-a]pyrimidine (IV) backbones were designed and synthesized for PDE10A interaction. Among these compounds, 1H-1,3-benzodiazoles and imidazo [1,2-a]pyrimidines showed the highest affinity for PDE10A enzyme as well as good metabolic stability. Both classes of compounds were identified

  含有[1,2,4]三唑[1,5- a ]吡啶（I），吡唑并[1,5- a ]吡啶（II），1 H -1,3-苯并二唑（III）和咪唑[设计并合成了1,2- α ]嘧啶（IV）骨架用于PDE10A相互作用。在这些化合物中，1 H -1,3-苯并二唑和咪唑并[1,2- a ]嘧啶类化合物对PDE10A酶的亲和力最高，且代谢稳定性良好。这两类化合物均被鉴定为选择性和有效的PDE10A酶抑制剂。
• Benzimidazole derivatives
  申请人：Dorsch Dieter

  公开号：US20050272740A1

  公开（公告）日：2005-12-08

  Novel compounds of the formula I in which D, X, X′, W, Y, T and R 1 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

  公式I中的新化合物，其中D、X、X'、W、Y、T和R1如专利申请1所定义，是凝血因子Xa的抑制剂，可用于预防和/或治疗血栓性疾病以及治疗肿瘤。
• US7566789B2
  申请人：——

  公开号：US7566789B2

  公开（公告）日：2009-07-28
• Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa
  作者：Werner W.K.R Mederski、Dieter Dorsch、Soheila Anzali、Johannes Gleitz、Bertram Cezanne、Christos Tsaklakidis

  DOI：10.1016/j.bmcl.2004.04.097

  日期：2004.7

  Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.